Cargando…

Noxa and Mcl-1 expression influence the sensitivity to BH3-mimetics that target Bcl-xL in patient-derived glioma stem cells

The recurrence of Glioblastoma is partly attributed to the highly resistant subpopulation of glioma stem cells. A novel therapeutic approach focuses on restoring apoptotic programs in these cancer stem cells, as they are often deregulated. BH3-mimetics, targeting anti-apoptotic Bcl-2 family members,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vera, Mariana Belén, Morris-Hanon, Olivia, Nogueiras, Germán Ignacio, Ripari, Luisina Belén, Esquivel, Myrian Inés, Perez-Castro, Carolina, Romorini, Leonardo, Sevlever, Gustavo Emilio, Scassa, María Elida, Videla-Richardson, Guillermo Agustín
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9587994/ https://www.ncbi.nlm.nih.gov/pubmed/36273072 http://dx.doi.org/10.1038/s41598-022-20910-4

Ejemplares similares

Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199
por: García, Carolina Paola, et al.
Publicado: (2016)

Chemical hypoxia induces apoptosis of human pluripotent stem cells by a NOXA-mediated HIF-1α and HIF-2α independent mechanism
por: Isaja, Luciana, et al.
Publicado: (2020)

AT101 [(-)-Gossypol] Selectively Inhibits MCL1 and Sensitizes Carcinoma to BH3 Mimetics by Inducing and Stabilizing NOXA
por: Mallick, David J., et al.
Publicado: (2020)

Inhibition of Antiapoptotic BCL-XL, BCL-2, and MCL-1 Proteins by Small Molecule Mimetics
por: Dalafave, D.S., et al.
Publicado: (2010)

Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models
por: Cucarull, Blanca, et al.
Publicado: (2020)

Inhibition of MARCH5 ubiquitin ligase abrogates MCL1-dependent resistance to BH3 mimetics via NOXA
por: Subramanian, Aishwarya, et al.
Publicado: (2016)

Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma
por: Videla-Richardson, Guillermo A., et al.
Publicado: (2021)

Effect of Antibiotics against Mycoplasma sp. on Human Embryonic Stem Cells Undifferentiated Status, Pluripotency, Cell Viability and Growth
por: Romorini, Leonardo, et al.
Publicado: (2013)

The Cell Cycle Inhibitors p21(Cip1) and p27(Kip1) Control Proliferation but Enhance DNA Damage Resistance of Glioma Stem Cells
por: Morris-Hanon, Olivia, et al.
Publicado: (2017)

LGG-11. BH3-MIMETICS TARGETING BCL-XL SELECTIVELY IMPACT THE SENESCENT COMPARTMENT OF PILOCYTIC ASTROCYTOMA
por: Selt, Florian, et al.
Publicado: (2021)

Bim escapes displacement by BH3-mimetic anti-cancer drugs by double-bolt locking both Bcl-XL and Bcl-2
por: Liu, Qian, et al.
Publicado: (2019)

Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B
por: Rooswinkel, R W, et al.
Publicado: (2012)

Human embryonic stem cells display a pronounced sensitivity to the cyclin dependent kinase inhibitor Roscovitine
por: Videla-Richardson, Guillermo A., et al.
Publicado: (2019)

Photodynamic Therapy Combined with Bcl-2/Bcl-xL Inhibition Increases the Noxa/Mcl-1 Ratio Independent of Usp9X and Synergistically Enhances Apoptosis in Glioblastoma
por: Golla, Carolin, et al.
Publicado: (2021)

A novel BH3-mimetic, AZD0466, targeting BCL-XL and BCL-2 is effective in pre-clinical models of malignant pleural mesothelioma
por: Arulananda, Surein, et al.
Publicado: (2021)

Acute severe hypoxia induces apoptosis of human pluripotent stem cells by a HIF-1α and P53 independent mechanism
por: Mucci, Sofía, et al.
Publicado: (2022)

A direct comparison of selective BH3-mimetics reveals BCL-X(L), BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma
por: Bierbrauer, Annika, et al.
Publicado: (2020)

NOXA-dependent contextual synthetic lethality of BCL-XL inhibition and “osmotic reprogramming” in colorectal cancer
por: Knoll, Gertrud, et al.
Publicado: (2020)

Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL
por: Le Pen, J, et al.
Publicado: (2016)

Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL
por: Le Pen, J, et al.
Publicado: (2017)

BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival
por: Lee, Erinna F., et al.
Publicado: (2019)

Low carbohydrate diet prevents Mcl-1-mediated resistance to BH3-mimetics
por: Rubio-Patiño, Camila, et al.
Publicado: (2016)

Apoptosis induced by overall metabolic stress converges on the Bcl-2 family proteins Noxa and Mcl-1
por: Wensveen, Felix M., et al.
Publicado: (2011)

First MCL-1-selective BH3 mimetics as potential therapeutics for targeted treatment of cancer
por: Besbes, S, et al.
Publicado: (2015)

Deubiquitinase USP13 dictates MCL1 stability and sensitivity to BH3 mimetic inhibitors
por: Zhang, Shengzhe, et al.
Publicado: (2018)

Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
por: Moujalled, Donia M., et al.
Publicado: (2018)

A same‐day assay predicts apoptotic response to combined BCL‐2 and MCL‐1 BH3‐mimetic targeting in multiple myeloma cells
por: Grundy, Martin, et al.
Publicado: (2020)

MiRNA-16-1 Suppresses Mcl-1 and Bcl-2 and Sensitizes Chronic Lymphocytic Leukemia Cells to BH3 Mimetic ABT-199
por: Ashofteh, Nooshin, et al.
Publicado: (2022)

A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors
por: Manzella, Gabriele, et al.
Publicado: (2021)

Bim, Puma and Noxa upregulation by Naftopidil sensitizes ovarian cancer to the BH3-mimetic ABT-737 and the MEK inhibitor Trametinib
por: Florent, Romane, et al.
Publicado: (2020)

The novel BH3 α-helix mimetic JY-1-106 induces apoptosis in a subset of cancer cells (lung cancer, colon cancer and mesothelioma) by disrupting Bcl-xL and Mcl-1 protein–protein interactions with Bak
por: Cao, Xiaobo, et al.
Publicado: (2013)

BH4 domain peptides derived from Bcl-2/Bcl-XL as novel tools against acute pancreatitis
por: Vervliet, Tim, et al.
Publicado: (2018)

Protocol for morphometric analysis of neurons derived from human pluripotent stem cells
por: Mucci, Sofía, et al.
Publicado: (2022)

Increased MCL1 dependency leads to new applications of BH3-mimetics in drug-resistant neuroblastoma
por: Jacob, Maureen, et al.
Publicado: (2023)

Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma
por: Shang, Enyuan, et al.
Publicado: (2020)

MCL1 and BCL-xL Levels in Solid Tumors Are Predictive of Dinaciclib-Induced Apoptosis
por: Booher, Robert N., et al.
Publicado: (2014)

Computational design of an apoptogenic protein that binds BCL-xL and MCL-1 simultaneously and potently
por: Kim, Seonghoon, et al.
Publicado: (2022)

The BCL-2 inhibitor ABT-199/venetoclax synergizes with proteasome inhibition via transactivation of the MCL-1 antagonist NOXA
por: Weller, Sandra, et al.
Publicado: (2022)

Combined inhibition of BCL-2 and MCL-1 overcomes BAX deficiency-mediated resistance of TP53-mutant acute myeloid leukemia to individual BH3 mimetics
por: Carter, Bing Z., et al.
Publicado: (2023)

Targeting BCL-2–expressing basal-like breast cancer with BH3-mimetics
por: Oakes, SR, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_a8k3bkamto3g8g2ao5fggj23kv